Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Long-Term Safety of Bisphosphonates

Open access
Ott, Susan M.·2005·The Journal of Clinical Endocrinology & Metabolism

Abstract

Bisphosphonates are widely used to treat osteoporosis. They reduce the incidence of new fractures in patients with established osteoporosis (1, 2). In women with osteopenia, bisphosphonates prevent bone loss, and physicians prescribe them with the hope of preventing future fractures. These medications have profound effects on bone physiology, but the long-term consequences remain unknown. The longest duration of placebo-controlled trials is 6 yr; subjects in observational studies have used the newer amino-bisphosphonates for 10 yr. Some unadvertised aspects of bisphosphonates, including their long half-life and their effects on bone physiology, are not well recognized. Unlike most medications, bisphosphonates remain in the body for decades. These drugs are not metabolized, but are either excreted renally or deposited within the bones. The amount of drug within the bone will accumulate with use. There is no known method of removing the medication from the bones. The duration of physiological effect is still unknown. After taking alendronate for 5 yr, the bone resorption and formation markers remain suppressed for at least 5 yr after discontinuation (3). The amino-bisphosphonates strongly inhibit osteoclastic bone resorption. During normal bone remodeling, osteoblastic bone formation follows resorption and occurs within the eroded cavities, so inhibition of bone resorption also results in inhibition of bone formation. Bone biopsy studies using double tetracycline labels show that the bone-forming surface is suppressed by 60–90% with usual doses of the bisphosphonates (4, 5). These drugs are certainly not anabolic! The volume of bone does not increase. The bone density as measured by dual-energy x-ray absorptiometry, however, does increase. This is because the bone is no longer remodeling, and so there is not much new bone. The older bone is denser than the newer bone; there is less water and more mineral in the bone, and the radiographic techniques thus measure the higher density. Osteoporotic bone is generally undermineralized, so some increase in mineralization (or hardening of the bone) may improve the bone strength (6). Bone that has been treated with bisphosphonate is still able to show an anabolic response to intermittent PTH, although the effect is blunted (7). Thus, fortunately, the profound bisphosphonate suppression of bone formation is at least partly reversible. By inhibiting bone resorption, bisphosphonates reduce the chance that trabecular plates will perforate. This has been shown with three-dimensional computed tomography scans of bone biopsies. Placebo-treated bones lose bone mass because they continue to have excess bone resorption, which leads to perforation of trabecular plates. This starts a vicious cycle of additional bone resorption because isolated trabecular rods have lost their mechanical signaling. As bone structure is lost, abnormal stress is placed on the remaining structures, which increases the possibility of damage and further stimulates bone turnover. Osteoblastic bone formation increases, but not enough to replace all of the lost bone or restore the trabecular architecture, so the overall bone mass decreases. The antiresorptive drugs halt this vicious cycle, and we think this is the major mechanism for improving bone strength. Once bone resorption has been inhibited to a certain degree, there is probably no benefit to further inhibition. Thus, the relative reduction in risk of fractures with antiresorbing medications is not closely linked to the increase in the bone density (8, 9). For example, in the risedronate hip fracture study (1), the decrease in hip fractures with 2.5 mg/d was statistically significantly different from placebo. With 5.0 mg/d, however, the relative risk of hip fractures was not statistically different from placebo, despite a greater bone density. Although combinations of antiresorptive medications may result in greater increases in bone density, the clinical trials have not had enough subjects to show any evidence that fracture risk is further reduced. A major question is: can potent inhibition of bone turnover be harmful? Two separate but related consequences of this inhibition are increased mineralization and accumulation of microdamage. As bone mineralization increases, the bone becomes brittle. This has been demonstrated by biomechanical measurements of bones that show a wide range of mineralization (10). The brittle bone might be more susceptible to fracture, but we don’t know the optimal mineralization density for the human skeleton. Microcracks occur in normal bone after the kind of stresses encountered in day-to-day life. These cracks are detected by the osteocytes, which initiate a bone-remodeling unit to repair the damage. If bone resorption is strongly inhibited, the damage can’t be repaired because the osteoclasts won’t dissolve the bone. In animals given high doses of bisphosphonates, microdamage accumulation is observed (11). The biologica

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2005-0057

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 241

Metadata

Authors
Ott, S. M.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2005-03-01
Volume
90
Issue
3
Pages
1897-1899
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2152462404
Cited by
241
References
2
FWCI
24.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Safety of Bisphosphonates. https://app.cochat.ai/papers/10.1210/jc.2005-0057
The paper
Ott, S. M. (2005). Long-Term Safety of Bisphosphonates. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-0057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.